Released on = June 18, 2006, 8:41 pm

Press Release Author = Marketing Communications, Covance Inc.

Industry = Pharmaceuticals

Press Release Summary = Covance Appoints Dr. Jeffrey J. Stoddard to Lead Risk
Management and Postmarketing Programs

- Also leads Covance Risk Management Expert Panel to help biopharmaceutical sponsors
build risk management into core of their development processes -


Press Release Body = Princeton, NJ, June 19, 2006 - Covance Inc. (NYSE: CVD) today
announced the appointment Jeffrey J. Stoddard, M.D. as Covance\'s Vice President,
Medical and Scientific Affairs, Risk Management and Postmarketing Programs. In this
capacity, Dr. Stoddard will lead Covance\'s risk management and postmarketing
business and have responsibility for providing scientific and technical leadership
in these important areas.

This move strengthens Covance\'s leadership team, in light of the increasing
regulatory and public scrutiny around biopharmaceutical product safety and the
ongoing need to document benefit in diverse populations. It also improves the
company\'s ability to help biopharmaceutical firms proactively address signal
detection, risk minimization, pharmacovigilance and benefit characterization from
the earliest stages of development, through to patient access and approved products.

\"Dr. Stoddard\'s broad background of medical practice, his close links with leading
academic institutions and government agencies, and his work on vaccines in
vulnerable populations make him the ideal person to meet the industry\'s growing need
for leadership in risk management and benefit characterization,\" said Dr. Larry
Meinert, Covance\'s Senior Vice President, Medical and Scientific Affairs. \"Working
within a scientific and operational community that spans the drug development
continuum from early, to late-stage and commercialization, Dr. Stoddard and his team
will be able to help Covance clients build risk management into the core of their
development processes.\"

\"Covance is uniquely positioned to meet pharmaceutical manufacturers\' needs from
preclinical testing through marketed product,\" said Stoddard. \"The ability to look
at data throughout the development continuum from various phases and incorporate it
into research design can significantly increase public safety and help practitioners
optimally use pharmaceutical products.\"
Dr. Stoddard will lead the Covance Risk Management Expert Panel, an internal team of
scientific experts in preclinical and clinical research, regulatory affairs, drug
safety, epidemiology and commercialization. This panel provides clients with
comprehensive risk management consulting from preclinical testing through
commercialization.

Prior to joining Covance, Dr. Stoddard was Senior Director, Medical Affairs at
MedImmune, a biopharmaceutical company, and also a physician researcher for the
Center for Studying Health System Change. Dr. Stoddard held numerous staff
appointments practicing medicine. His areas of research focus include vaccines,
preventative medicine and pediatrics.

Dr. Stoddard earned a Doctorate of Medicine from the University of Wisconsin Medical
School, performed a postdoctoral fellowship at the University of California, San
Francisco, and completed residency at The Johns Hopkins Hospital, Department of
Pediatrics. Dr. Stoddard publishes frequently, holds numerous memberships and
appointments, and presents at industry conferences.

About Covance Risk Management and Postapproval Program Services

Covance designs and implements postapproval risk minimization programs that optimize
product safety and effectiveness. This includes addressing unanswered safety
questions, meeting regulatory requirements, confirming and validating effectiveness
in real-world use, better defining the safety profile and providing a cornerstone
for Risk Management. Covance scientific and operations teams work with
biopharmaceutical clients to determine the best solution for desired outcomes,
designing unique solutions for risk management and evaluation, from design through
execution, analysis and reporting.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world\'s largest
and most comprehensive drug development services companies with annual revenues
greater than $1 billion, global operations in more than 20 countries, and more than
7,400 employees worldwide. Information on Covance\'s products and services, recent
press releases, and SEC filings can be obtained through its website at
www.covance.com.



Web Site = http://www.covance.com

Contact Details = 210 Carnegie Center
Princeton, NJ 08540
Media Relations +1 (609) 452-4159
pr@covance.com